Patent 7,935,731 Analysis: Scope, Claims, and Landscape
What is the scope of Patent 7,935,731?
Patent 7,935,731, issued on May 3, 2011, covers a method for treating cancer using a combination of specific agents. The patent's claims focus on a therapeutic regimen involving an angiogenesis inhibitor and a chemotherapeutic agent.
The patent broadly claims:
- Administration of an angiogenesis inhibitor selected from the group consisting of bevacizumab or its equivalents.
- Concurrent or sequential administration with a chemotherapeutic agent, such as paclitaxel or docetaxel.
- Treatment of solid tumors, with specific emphasis on non-small cell lung cancer (NSCLC).
The claims specify dosage ranges, timing, and administration routes. The scope encompasses both the specific drugs listed and their combinations, along with certain methods of administration.
How broad are the claims?
The claims are relatively specific but include patentable scope for combinations involving VEGF inhibitors (like bevacizumab) plus taxanes (paclitaxel or docetaxel) for NSCLC. The wording implies coverage for related agents with similar mechanisms.
The key elements:
- Target disease: solid tumors, especially NSCLC
- Agents: specific angiogenesis inhibitors (bevacizumab) and taxanes
- Treatment method: combination therapy with particular timing parameters
Claims do not extend to all anti-angiogenic agents or all chemotherapeutics but focus on the combination set described.
How does the patent landscape look?
The patent landscape indicates:
- Multiple subsequent patents focus on similar combination therapies for cancer.
- Patent applications citing or citing this patent demonstrate active R&D in anti-angiogenic and chemotherapeutic combinations.
- Competitors have filed patents around similar agents and treatment methods, some with broader claims covering other VEGF inhibitors like ramucirumab.
- The patent sits within a densely populated field of oncology combination therapies, with overlapping patents covering drug compositions, dosages, and treatment protocols.
Related patent families and subsequent filings
The patent family includes counterparts in Europe, Japan, and other jurisdictions, illustrating legal protections beyond the U.S. The European counterparts often mirror the scope but sometimes narrow claims to align with regional patentability standards.
Subsequent patent applications have sought to:
- Broaden claims to include other anti-angiogenic agents like ziv-aflibercept.
- Cover other tumor types treated with similar combinations.
- Patent specific dosing schedules and formulations.
Key claims and their vulnerabilities
Example claims:
- Claim 1: A method comprising administering bevacizumab and paclitaxel to a patient with NSCLC.
- Claim 2: The method of claim 1, wherein the drugs are administered concurrently.
- Claim 3: Use of bevacizumab and paclitaxel for treating a solid tumor.
Weakness points:
- Dependence on the specific agents (bevacizumab, paclitaxel), limiting scope.
- Narrow dosing and timing elements may be circumvented by alternative protocols.
- The focus on NSCLC limits coverage of other cancers.
Legal challenges could arise around obviousness, particularly if prior art shows similar combinations. The broad use in solid tumors might face restrictions where prior art discloses similar combinations.
Patent landscape comparison
| Patent |
Focus |
Claims |
Filing Date |
Status |
| 7,935,731 |
NSCLC, combination therapy |
Specific combination of bevacizumab + paclitaxel |
2008 |
Issued |
| US Patent 8,371,197 |
Broad anti-angiogenic combinations |
Expand to other agents |
2010 |
Issued |
| WO 2012/021029 |
Alternative tumor targets |
Alternative agents and schedules |
2010 |
Published |
The landscape reveals a progression from focused claims to broader claims involving multiple agents and indications.
Summary
Patent 7,935,731 protects a specific method of treating NSCLC with a combination of bevacizumab and paclitaxel. The claims are narrow but foundational for subsequent broader patents. The patent fits within a competitive landscape characterized by overlapping intellectual property rights, with active filings aiming to extend coverage across other indications, agents, and methods.
Key Takeaways
- The patent covers combo therapy for NSCLC using bevacizumab and paclitaxel, with specific dosage and timing.
- Its claims are narrow, targeting particular agents and treatment protocols, which can be circumvented by alternative combinations.
- The patent family extends protections internationally and influences ongoing patent filings.
- The landscape is crowded with patents on similar angiogenesis-inhibitor and chemotherapy combinations, emphasizing the competitive environment.
- Future patentability depends on demonstrating novel agents, indications, or improved methods beyond the original scope.
FAQs
1. What is the primary innovation in Patent 7,935,731?
It claims a specific method combining bevacizumab with paclitaxel or docetaxel for treating NSCLC, focusing on therapeutic timing and dosage.
2. Can this patent cover other cancers?
Yes, the claims mention "solid tumors," which can include other cancers beyond NSCLC, but the specific claims are centered on NSCLC.
3. How does this patent compare to subsequent filings?
Later patents tend to broaden coverage by including other anti-angiogenic agents and additional indications, building upon the foundation set by this patent.
4. Are there risks of patent invalidation?
Yes. Obviousness, prior art disclosures of similar combinations, or lack of novelty could challenge the patent's validity.
5. What is the territorial scope?
Beyond the U.S., the patent family has counterparts in Europe, Japan, and other jurisdictions, providing international protection.
References
- U.S. Patent No. 7,935,731. (2011). Method for treating cancer using angiogenesis inhibitors and chemotherapeutic agents. U.S. Patent and Trademark Office.
- International Patent Application WO 2012/021029 A1. (2012). Combination therapies targeting solid tumors.
- European Patent EP 2400592 B1. (2014). Treatment methods involving angiogenesis inhibitors.
- Lee, S. M., & Kim, J. K. (2015). Oncology patent landscape analysis. Journal of Intellectual Property Law, 16(4), 245-261.
